scholarly journals Monitoring influenza vaccine effectiveness using the national influenza surveillance system

2014 ◽  
Vol 24 (suppl_2) ◽  
Author(s):  
A Machado ◽  
MG Freitas ◽  
R Guiomar ◽  
CM Dias ◽  
B Nunes
Keyword(s):  
Influenza Vaccine ◽  
Surveillance System ◽  
Vaccine Effectiveness ◽  
Influenza Surveillance

scholarly journals Pooled influenza vaccine effectiveness estimates for Australia, 2012–2014

2016 ◽  
Vol 144 (11) ◽  
pp. 2317-2328 ◽  
Author(s):  
S. G. SULLIVAN ◽  
K. S. CARVILLE ◽  
M. CHILVER ◽  
J. E. FIELDING ◽  
K. A. GRANT ◽  
...  
Keyword(s):  
General Practice ◽  
Logistic Regression ◽  
Confidence Interval ◽  
Influenza Vaccine ◽  
Sample Size ◽  
Vaccine Coverage ◽  
Vaccine Effectiveness ◽  
Influenza Surveillance ◽  
Influenza B ◽  
Age Group

SUMMARYData were pooled from three Australian sentinel general practice influenza surveillance networks to estimate Australia-wide influenza vaccine coverage and effectiveness against community presentations for laboratory-confirmed influenza for the 2012, 2013 and 2014 seasons. Patients presenting with influenza-like illness at participating GP practices were swabbed and tested for influenza. The vaccination odds of patients testing positive were compared with patients testing negative to estimate influenza vaccine effectiveness (VE) by logistic regression, adjusting for age group, week of presentation and network. Pooling of data across Australia increased the sample size for estimation from a minimum of 684 to 3,683 in 2012, from 314 to 2,042 in 2013 and from 497 to 3,074 in 2014. Overall VE was 38% [95% confidence interval (CI) 24–49] in 2012, 60% (95% CI 45–70) in 2013 and 44% (95% CI 31–55) in 2014. For A(H1N1)pdm09 VE was 54% (95% CI–28 to 83) in 2012, 59% (95% CI 33–74) in 2013 and 55% (95% CI 39–67) in 2014. For A(H3N2), VE was 30% (95% CI 14–44) in 2012, 67% (95% CI 39–82) in 2013 and 26% (95% CI 1–45) in 2014. For influenza B, VE was stable across years at 56% (95% CI 37–70) in 2012, 57% (95% CI 30–73) in 2013 and 54% (95% CI 21–73) in 2014. Overall VE against influenza was low in 2012 and 2014 when A(H3N2) was the dominant strain and the vaccine was poorly matched. In contrast, overall VE was higher in 2013 when A(H1N1)pdm09 dominated and the vaccine was a better match. Pooling data can increase the sample available and enable more precise subtype- and age group-specific estimates, but limitations remain.

scholarly journals Estimates of Influenza Vaccine Effectiveness for 2007–2008 From Canada's Sentinel Surveillance System: Cross-Protection Against Major and Minor Variants

2012 ◽  
Vol 205 (12) ◽  
pp. 1858-1868 ◽  
Author(s):  
Naveed Z. Janjua ◽  
Danuta M. Skowronski ◽  
Gaston De Serres ◽  
Jim Dickinson ◽  
Natasha S. Crowcroft ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Surveillance System ◽  
Vaccine Effectiveness ◽  
Sentinel Surveillance ◽  
Cross Protection ◽  
Sentinel Surveillance System

scholarly journals Identifying early changes in influenza vaccination uptake following a government funded immunisation program using a participatory community surveillance program

2020 ◽  
Vol 44 ◽  
Author(s):  
Sarah A Moberley ◽  
Sandra J Carlson ◽  
David N Durrheim ◽  
Craig B Dalton
Keyword(s):  
Influenza Vaccine ◽  
Surveillance System ◽  
Vaccine Coverage ◽  
Age Groups ◽  
Influenza Surveillance ◽  
Surveillance Program ◽  
Community Based ◽  
Influenza Like Illness ◽  
National Immunisation ◽  
The University

Following Australia’s severe influenza season in 2017, the health departments of the states and territories commenced funding in 2018 of influenza vaccine for all children aged six months to five years. As the national immunisation register has recently been extended to include recording of vaccination for all age groups, Australia’s community-based influenza-like illness (ILI) surveillance system, Flutracking, was used to explore influenza vaccine coverage in participants. Flutracking participants respond to a weekly survey about ILI from April to October each year. Participants report their influenza vaccine status with the current year’s vaccine in the first weekly survey, and if unvaccinated (or unknown), participants are prompted with the question weekly until the end of the Flutracking season. Detailed methods for Flutracking are available elsewhere.1 Self-reported vaccine coverage by age group (<5 years, 5 to 17 years, 18 to 64 years and ≥65 years) was calculated at 21 October (timing of the final 2018 Flutracking survey) for participants who had completed at least one survey in 2018. The five-year average was calculated for the percentage vaccinated at the end of the Flutracking survey for the years 2013 to 2017, and compared to 2018. Flutracking received ethics approval from the University of Newcastle (# 06/03/22.403) in 2006. In 2009 the program applied to the University of Newcastle to exit the ethics committee review as Flutracking had been incorporated into the national influenza surveillance system. The total number of participants completing at least one survey increased from 18,437 in 2013 to 45,532 in 2018. Flutracking participants are more likely to be female (59.8% compared to 50.4%) and more likely to have completed a postgraduate degree (22.6% compared to 3.6%) than the general Australian population.2 A relatively large proportion of Flutracking participants are health care workers, working face to face with patients (17.5%). Keywords: flutracking, vaccine coverage, influenza vaccine, influenza like illness, community based surveillance

scholarly journals Concordance of interim and final estimates of influenza vaccine effectiveness: a systematic review

2016 ◽  
Vol 21 (16) ◽  
Author(s):  
Vivian K Leung ◽  
Benjamin J Cowling ◽  
Shuo Feng ◽  
Sheena G Sullivan
Keyword(s):  
Influenza Vaccine ◽  
Influenza A ◽  
Seasonal Influenza ◽  
Vaccine Effectiveness ◽  
World Health ◽  
Absolute Difference ◽  
Influenza Surveillance ◽  
Influenza B ◽  
Surveillance And Response ◽  
Influenza A H1n1

The World Health Organization's Global Influenza Surveillance and Response System meets twice a year to generate a recommendation for the composition of the seasonal influenza vaccine. Interim vaccine effectiveness (VE) estimates provide a preliminary indication of influenza vaccine performance during the season and may be useful for decision making. We reviewed 17 pairs of studies reporting 33 pairs of interim and final estimates using the test-negative design to evaluate whether interim estimates can reliably predict final estimates. We examined features of the study design that may be correlated with interim estimates being substantially different from their final estimates and identified differences related to change in study period and concomitant changes in sample size, proportion vaccinated and proportion of cases. An absolute difference of no more than 10% between interim and final estimates was found for 18 of 33 reported pairs of estimates, including six of 12 pairs reporting VE against any influenza, six of 10 for influenza A(H1N1)pdm09, four of seven for influenza A(H3N2) and two of four for influenza B. While we identified inconsistencies in the methods, the similarities between interim and final estimates support the utility of generating and disseminating preliminary estimates of VE while virus circulation is ongoing.

scholarly journals 1338. Before and After: The Impact of the COVID-19 Pandemic on Influenza-Like Illness Trends in PAIVED

2021 ◽  
Vol 8 (Supplement_1) ◽  
pp. S756-S757
Author(s):  
Rhonda E Colombo ◽  
Stephanie A Richard ◽  
Christina Schofield ◽  
Limone Collins ◽  
Anuradha Ganesan ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Pathogen Detection ◽  
Demographic Data ◽  
Panel Member ◽  
Vaccine Effectiveness ◽  
Mitigation Measures ◽  
Influenza Surveillance ◽  
Review Panel ◽  
Influenza Like Illness ◽  
The Impact

Abstract Background The Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD (PAIVED) is a multicenter study assessing influenza vaccine effectiveness in active duty service members, retirees, and dependents. PAIVED recently completed its third year and offers a unique opportunity to examine influenza-like illness (ILI) trends prior to and during the COVID-19 pandemic in a prospective, well-defined cohort. Methods During the 2018-19, 2019-20, and 2020-21 influenza seasons, PAIVED enrolled DoD beneficiaries presenting for annual influenza vaccination. After collecting baseline demographic data, participants were randomized to receive egg-based, cell-based, or recombinant-derived influenza vaccine. Weekly throughout the influenza season of enrollment, participants were surveyed electronically for ILI, defined as (1) having cough or sore throat, plus (2) feeling feverish/having chills or having body aches/fatigue. Participants with ILI completed a daily symptom diary for seven days and submitted a nasal swab for pathogen detection. Results Over the three seasons, there were 10,656 PAIVED participants: 1514 (14.2%) in 2018-19, 5876 (55.1%) in 2019-20, and 3266 (30.6%) in 2020-21. The majority were male (68-73% per year) with a mean age of 34±14.8 years at enrollment. 2266 participants reported a total of 2673 unique ILIs. The highest percentage of participants with ILI was in 2019-20 (28.2%), versus 19.6% in 2018-19 and 9.6% in 2020-21. Figure 1 depicts the percent of individuals reporting ILI by week of the season for each of the PAIVED seasons. Notably, after March 21, 2020, the weekly incidence of participants reporting ILI never exceeded 1%. Figure 1. Percent of PAIVED participants reporting ILI by week of season. Conclusion The low incidence of reported ILI in PAIVED participants during the COVID-19 pandemic is consistent with national influenza surveillance reports of influenza and outpatient ILI activity, suggesting that mitigation measures taken to reduce transmission of SARS-CoV-2 reduced the spread of other respiratory viruses. Disclaimer Disclosures Ryan C. Maves, MD, EMD Serono (Advisor or Review Panel member)Heron Therapeutics (Advisor or Review Panel member) Jitu Modi, MD, GSK (Speaker’s Bureau)

Sign in / Sign up

Export Citation Format

Share Document